Post-traumatic stress disorder (PTSD)

Post-traumatic stress disorder (PTSD) is a psychiatric health response to a traumatic event. Symptoms of post-traumatic stress may include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. These symptoms may persist long after the triggering event, and may be unresponsive to conventional therapeutic treatments. An estimated one in ten Americans suffers from post-traumatic stress.

The endogenous cannabinoid system is believed to play a “critical role … in the etiology of PTSD in humans.”[1] Researchers theorize, “Cannabis may dampen the strength or emotional impact of traumatic memories through synergistic mechanisms that might make it easier for people with PTSD to rest or sleep and to feel less anxious and less involved with flashback memories. … Evidence is increasingly accumulating that cannabinoids might play a role in fear extinction and anti-depressive effects.”[2]

Placebo-controlled clinical data assessing cannabis’ impact on PTS is not yet available. Observational data provide mixed results. A retrospective review of patients’ symptoms published in 2014 in theJournal of Psychoactive Drugs reported a greater than 75 percent reduction CAPS (Clinician Administered Posttraumatic Scale) symptom scores following cannabis therapy.[3] But a larger observational study of PTS subjects reported that “those who never used marijuana had significantly lower symptom severity four months later than those who continued or started use after treatment.”[4]Similarly, a 2015 case-control study found no association between self-reported cannabis use and mental health symptom severity in a cohort of Veterans with probably PTSD.[5]

Small clinical trials assessing the use of individual cannabinoids have shown success in PTS treatment. A 2014 Israeli trial reported that the adjunctive administration of orally absorbable THC “caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms” in a cohort of ten subjects.[6] Separate trials report that the administration of nabilone, a synthetic cannabinoid, safely mitigates various symptoms of post-traumatic stress, including insomnia, chronic pain, and treatment-resistant nightmare.[7-8]

Consequently, some investigators now believe that targeting the endogenous cannabinoid system may “provide a foundation upon which to develop and validate informative biomarkers of PTSD vulnerability, as well as to guide the rational development of the next generation of evidence-based treatments for PTSD.”[9]


[1] Nuemeister et al. 2013. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry 18: 1034-1040

[2] Passie et al. Mitigation of post-traumatic stress symptoms by cannabis resin: A review of the clinical and neurobiological evidence. Drug Testing and Analysis 4: 649-659

[3] Greer et al. 2014. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. Journal of Psychoactive Drugs 46: 73-77.

[4] Medscape. December 15, 2004. “Medical marijuana may worsen PTSD symptoms, increase violence.”

[5] Johnson et al. Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD. Journal of Affective Disorders 190: 439-442.

[6] Roitman et al. 2014. Preliminary, open-label, pilot study of add-on oral delta-9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical Drug Investigation 34: 587-591.

[7] Cameron et al. 2014. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. Journal of Clinical Psychopharmacology 34: 559-564.

[8] Fraser G. 2009. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics 15: 84-88.

[9] Nuemeister et al. 2013. Op. cit.